Medication persistence in children and young people on long-term, grass pollenspecific immunotherapy - Measured by prescription renewal rates;Medikamenten-Persistenz bei Kindern und Jugendlichen unter einer Langzeit-Hyposensensibilisierung mit Gräserpollenextrakten: Ergebnisse einer Versorgungsstudie anhand von Verordnungsdaten

Allergologie

Volumn 36, Issue 1, 2013, Pages 9-18

  Eberle, P ^a   Schreder, H ^b   Shah Hosseini, K ^c   Mosges R ^c  

^a Kinder und Jugendmedizin Allergologie   (Germany)

^b Stallergenes GmbH   (Germany)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Adolescents; Children; Medication persistence; Non interventional study; Prescription renewal rates; Specific immunotherapy

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHILD; GRASS POLLEN; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRESCRIPTION; SCHOOL CHILD; SPECIFIC IMMUNOTHERAPY; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY;

EID: 84873842751     PISSN: 03445062     EISSN: None     Source Type: Journal    
DOI: 10.5414/alx01536     Document Type: Article

References (23)

1. Bufe A, Eberle P, Franke-Beckmann E, FunckJ, Kimmig M, Klimek L, Knecht R, Stephan V,Tholstrup B, Weisshaar C, Kaiser F. Safety andefficacy in children of an SQ-standardized grassallergen tablet for sublingual immunotherapy.J Allergy Clin Immunol. 2009; 123: 167-173.doi:10.1016/j.jaci.2008.10.044 PubMed
2. Cramer JA, Bradley-Kennedy C, Scalera A. Treatmentpersistence and compliance with medicationsfor chronic obstructive pulmonary disease. Can Respir J. 2007; 14: 25-29. PubMed
3. Cramer JA, Roy A, Burrell A, Fairchild CJ,Fuldeore MJ, Ollendorf DA, Wong PK. Medicationcompliance and persistence: terminologyand definitions. Value Health. 2008; 11: 44-47.doi:10.1111/j.1524-4733.2007.00213.x PubMed
4. Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W, Till SJ, Hamid QA, Nouri-Aria KT. Long-term clinical efficacy of grasspollenimmunotherapy. N Engl J Med. 1999; 341:468-475. doi:10.1056/ NEJM199908123410702PubMed
5. Durham SR, Emminger W, Kapp A, Colombo G, de Monchy JG, Rak S, Scadding GK, Andersen JS,Riis B, Dahl R. Long-term clinical efficacy in grasspollen-induced rhinoconjunctivitis after treatmentwith SQ-standardized grass allergy immunotherapytablet. J Allergy Clin Immunol. 2010; 125:131-138. doi:10.1016/j.jaci.2009.10.035 PubMed
6. Egert-Schmidt AM, Martin E, Müller J, SchulteM, Thum-Oltmer S. Patienten-Compliance in derSpezifischen Immuntherapie - ein Vergleich vonSCIT- und SLIT-Präparaten. Poster anläßlich des 6. Deutschen Allergiekongresses, Wiesbaden, 7.bis 10. September 2011.
7. Fachinformation POLLINEX Quattro, Stand Juni2011.
8. Hasford J, Uricher J, Tauscher M, Bramlage P,Virchow JC. Persistence with asthma treatment islow in Germany especially for controller medication- a population based study of 483,051 patients. Allergy. 2010; 65: 347-354. doi:10.1111/j.1398-9995.2009.02161.x PubMed
9. Karlstad O, Nafstad P, Tverdal A, Skurtveit S,Furu K. Prevalence, incidence and persistence ofanti-asthma medication use in 2- to 29-year-olds:a nationwide prescription study. Eur J Clin Pharmacol.2010; 66: 399-406. doi:10.1007/s00228-009-0749-x PubMed
10. Kleine-Tebbe J, et al. Die spezifische Immuntherapie(Hyposensibilisierung) bei IgE-vermitteltenallergischen Erkrankungen. Leitlinie der DeutschenGesellschaft für Allergologie und klinischeImmunologie (DGAKI), des ÄrzteverbandesDeutscher Allergologen (ÄDA), der Gesellschaftfür Pädiatrische Allergologie und Umweltmedizin(GPA), der Österreichischen Gesellschaft fürAllergologie und Immunologie (ÖGAI) und derSchweizerischen Gesellschaft für Allergologieund Immunologie (SGAI). Allergo J. 2009; 18:508-537.
11. Möller C, Dreborg S, Ferdousi HA, Halken S,Høst A, Jacobsen L, Koivikko A, Koller DY,Niggemann B, Norberg LA, Urbanek R, ValovirtaE, Wahn U. Pollen immunotherapy reduces thedevelopment of asthma in children with seasonalrhinoconjunctivitis (the PAT-study). J AllergyClin Immunol. 2002; 109: 251-256. doi:10.1067/mai.2002.121317 PubMed
12. Novembre E, Galli E, Landi F, Caffarelli C,Pifferi M, De Marco E, Burastero SE, CaloriG, Benetti L, Bonazza P, Puccinelli P, ParmianiS, Bernardini R, Vierucci A. Coseasonal sublingualimmunotherapy reduces the development ofasthma in children with allergic rhinoconjunctivitis.J Allergy Clin Immunol. 2004; 114: 851-857.doi:10.1016/j.jaci.2004.07.012 PubMed
13. Rak S. Long-term efficacy of a pre- and co-seasonallyadministered sublingual grass pollen immunotherapytablet. Vortrag anlässlich des 30thCongress of the European Academy of Allergyand Clinical Immunology (EAACI), Istanbul/Türkei 11. - 15. Juni 2011.
14. Röder E, Berger MY, de Groot H, Gerth van Wijk R. Sublingual immunotherapy in youngsters: adherence in a randomized clinical trial. ClinExp Allergy. 2008; 38: 1659-1667. doi:10.1111/j.1365-2222.2008.03060.x PubMed
15. Schüssel K, Leuner K, Schulz M, Müller WE. Persistenz und Compliance bei Antihypertensiva. Pharmazeutische Zeitung online, 2011.
16. Senna G, Lombardi C, Canonica GW, PassalacquaG. How adherent to sublingual immunotherapyprescriptions are patients? The manufacturers' viewpoint. J Allergy Clin Immunol. 2010; 126:668-669. doi:10.1016/j.jaci.2010. 06.045 PubMed
17. Senna G, Ridolo E, Calderon M, Lombardi C,Canonica GW, Passalacqua G. Evidence of adherenceto allergen-specific immunotherapy. CurrOpin Allergy Clin Immunol. 2009; 9: 544-548.doi:10.1097/ACI.0b013e328332b8df PubMed
18. Sieber J, De Geest S, Shah-Hosseini K, MösgesR. Medication persistence with long-term, specificgrass pollen immunotherapy measured byprescription renewal rates. Curr Med Res Opin.2011; 27: 855-861. doi:10.1185/03007995.2011.559538 PubMed
19. Sondermann N, Shah-Hosseini K, Henkel K,Schwalfenberg A, Mösges R. Erfolgsfaktoren derAdherence bei Hyposensibilisierung. Allergologie.2011; 34: 441-446.
20. Valovirta E, Berstad AK, de Blic J, Bufe A, EngP, Halken S, Ojeda P, Roberts G, Tommerup L,Varga EM, Winnergard I; GAP investigators. Designand recruitment for the GAP trial, investigatingthe preventive effect on asthma developmentof an SQ-standardized grass allergy immunotherapytablet in children with grass pollen-inducedallergic rhinoconjunctivitis. Clin Ther. 2011; 33:1537-1546. doi:10.1016/j.clinthera.2011.09.013PubMed
21. Wahn U, Tabar A, Kuna P, Halken S, Montagut A, de Beaumont O, Le Gall M; SLIT Study Group. Efficacy and safety of 5-grass-pollen sublingualimmunotherapy tablets in pediatric allergic rhinoconjunctivitis.J Allergy Clin Immunol. 2009; 123: 160-166. doi:10.1016/j.jaci.2008.10.009PubMed
22. WHO. Adherence to long-term therapies. Evidencefor action. Stand 2003. http://www.who.int/chp/knowledge/publications/adherence-report/en/index.html.
23. Zuidgeest MG, Smit HA, Bracke M, Wijga AH,Brunekreef B, Hoekstra MO, Gerritsen J, Kerkhof M, de Jongste JC, Leufkens HG; PIAMA-StudyGroup. Persistence of asthma medication use inpreschool children. Respir Med. 2008; 102: 1446-1451. doi:10.1016/j.rmed.2008.04.003 PubMed